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Abstract
Objective: ATP-binding-cassette transporter A7(ABCA7) is suggested to be
involved in lipid transport as well as in phagocytosis of amyloid-b in the brain.
We tested the hypothesis that a common genetic variant in ABCA7 is associated
with dementia, ischemic heart disease, ischemic cerebrovascular disease, and
with lipid levels in the general population, independent of the common
apolipoprotein E(APOE) genotype. Methods: For this purpose, we genotyped a
common genetic variant in ABCA7, identified in genome-wide-association-stu-
dies of Alzheimer’s disease, in 104,258 individuals from the Danish general
population, and also meta-analyzed our results with publicly available consortia
data. Results: Multifactorially adjusted hazard ratios for Alzheimer’s disease
were 1.07 (95% confidence interval:0.93–1.23) and 1.72 (1.24–2.40) for GA and
AA versus GG genotype. Results were similar after APOE genotype adjustment
and when only APOE ɛ33 carriers were studied. Including 178,304 individuals,
the meta-analyzed odds ratio for Alzheimer’s disease per one allele ABCA7
rs4147929 increase was 1.15 (1.12–1.18). ABCA7 genotype was not convincingly
associated with vascular dementia, ischemic heart disease, ischemic cerebrovas-
cular disease, or with lipid levels. Including 288,563 individuals, meta-analyzed
odds ratios for ischemic heart disease per one allele ABCA7 rs4147929 increase
was 1.01 (0.99–1.03). Interpretation: A common genetic variant in ABCA7 was
associated with high risk of Alzheimer’s disease independent of APOE genotype.
The lack of association with vascular dementia, ischemic heart disease, ischemic
cerebrovascular disease, and with lipid levels suggests that ABCA7 is not important
for atherosclerosis. Thus, our findings support the suggested role of ABCA7 in Alz-
heimer’s disease pathology and phagocytic clearance of amyloid-b in the brain.
Introduction
Forty-seven million people are currently living with Alz-
heimer’s disease or other types of dementia, a number
that is estimated to increase globally to 131 million in
2050.1 Recent demographic studies have shown a decrease
in incidences in developed countries most likely due to
improved treatment and prevention of vascular risk fac-
tors.2–4 Genome-wide association studies (GWAS) have
revealed novel molecular pathways, among these the
ATP-binding-cassette transporter A7 (ABCA7),5,6 which
may be involved in both transmembrane lipid transport
and phagocytosis of amyloid-b in the brain.7–14 Following
these GWAS findings, rare loss-of-function variants in
ABCA7 were reported to confer risk of Alzheimer’s dis-
ease in case–control studies in Icelandic and Belgian pop-
ulations.15,16 Whether common genetic variation in
ABCA7 confers risk of dementia, ischemic heart- and
cerebrovascular disease in the general population, and
whether potential associations are independent of the
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strong Alzheimer’s disease apolipoprotein E (APOE) ɛ4
risk allele remains to be determined.
Alzheimer’s disease is believed to be driven by the pro-
duction and deposition of neurotoxic sticky amyloid-b
peptides which aggregate into senile plaques in the
brain.17–20 ABCA7 is highly expressed in brain tissue,9,21,22
most abundant in microglia and oligodendrocytes.7,23
Previous studies comparing ABCA7 knock-out mice with
wild-type mice or J20 amyloidogenic mice demonstrate
that ABCA7 is involved in clearance of amyloid-b in the
brain through phagocytosis.12,24 Furthermore, early stud-
ies on ABCA7 explored lipid efflux capacities and sug-
gested that ABCA7 contributes to phospholipid and
cholesterol transport.8–10,21,25–27 Since ABCA7 may be
implicated in both Alzheimer’s disease pathology and
lipid metabolism, studying the impact of common genetic
variation in ABCA7 for risk of Alzheimer’s disease and
other types of dementia, lipid metabolism, ischemic heart
disease and ischemic cerebrovascular disease is of interest.
We tested the hypothesis that a common genetic vari-
ant in ABCA7 is associated with dementia, ischemic heart
disease, ischemic cerebrovascular disease and with lipid
levels in the general population, independent of the com-
mon APOE genotype. For this purpose, we genotyped the
rs4147929 genetic variant in ABCA7, previously identified
as a GWAS top hit for Alzheimer’s disease,5 as well as
APOE genotypes (rs7412 and rs429358) in a prospective
study of the general population totaling 104,258 individu-
als. Finally, in meta-analyses we included consortia data
from the International Genomics of Alzheimer’s Projects
(IGAP) including 74,046 individuals and the CARDIo-
GRAMplusC4D including 184,305 individuals.
Subjects and Methods
Studies were approved by institutional review boards and
Danish ethical committees, and conducted according to
the Declaration of Helsinki. Written informed consent
was obtained from all participants. All participants were
white and of Danish descent. There was no overlap of
individuals between studies.
Participants
Our study included participants from two similar prospec-
tive studies of the Danish general population in Denmark,
the Copenhagen General Population Study (CGPS) and the
Copenhagen City Heart Study (CCHS). Combining these
two studies yielded a total of 104,258 participants.
The CGPS was initiated in 2003, and enrollment is on-
going.28–30 Participants were selected with the use of the Dan-
ish Civil Registration System to reflect the adult Danish popu-
lation aged 20 to 100 + years. Data were obtained from a
self-administered questionnaire reviewed together with an
investigator on the day of attendance, a physical examination,
and from blood samples including DNA extraction. We
included 94,214 consecutive participants in the current analy-
ses. During follow-up (which ended in November 2014), 1145
were diagnosed with dementia, of whom 613 had Alzheimer’s
disease, 9039 were diagnosed with ischemic heart disease, and
5,975 were diagnosed with cerebrovascular disease.
CCHS baseline examinations were performed between
1976 and 1978 with follow-up examinations in 1981–1983,
1991–1994, and 2001–2003. Participants were recruited and
examined as in the CGPS. DNA was available from the
1991–1994 or 2001–2003 examinations. We included 10,044
consecutive participants in the current analysis. During fol-
low-up (which ended in November 2014), 915 were diag-
nosed with dementia, of whom 349 had Alzheimer’s disease,
2345 were diagnosed with ischemic heart disease, and 1363
were diagnosed with cerebrovascular disease.
Consortia data
International Genomics of Alzheimer’s Project
IGAP is a large two-stage study based upon GWAS on
individuals of European ancestry.5 In stage 1, IGAP used
genotyped and imputed data on 7,055,881 SNPs to meta-
analyze four previously published GWAS datasets
consisting of 17,008 Alzheimer’s disease cases and 37,154
controls (The European Alzheimer’s disease Initiative –
EADI the Alzheimer Disease Genetics Consortium – ADGC
The Cohorts for Heart and Aging Research in Genomic
Epidemiology consortium – CHARGE The Genetic and
Environmental Risk in AD consortium – GERAD). In stage
2, 11,632 SNPs were genotyped and tested for association
in an independent set of 8,572 Alzheimer’s disease cases
and 11,312 controls. Finally, a meta-analysis was performed
combining results from stages 1 and 2.
Coronary ARtery DIsease Genome wide
Replication and Meta-analysis plus The Coronary
Artery Disease (C4D) Genetics and 1000-Genomes-
based GWAS
CARDIoGRAMplusC4D 1000 Genomes-based GWAS is a
meta-analysis of GWAS studies mainly of European des-
cent using the 1000 Genomes phase 1 v3 training set with
38 million variants for imputing. The study interrogated
9.4 million variants and involved 60,801 ischemic heart
disease cases and 123,504 controls from 48 studies.31
Clinical endpoints
Information on births, deaths, emigrations, and immigra-
tions was collected from the national Danish Civil
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Registration System. Information on diagnoses of demen-
tia (International Classifications of Diseases (ICD) 8 290;
and ICD10 F00, F01, F03, G30), ischemic heart disease
(ICD8 410-414 and ICD10 I20-I25) and cerebrovascular
disease (ICD8 431-438 and ICD10 I60-I69, G45) was
drawn from the national Danish Patient Registry and the
national Danish Causes of Death Registry. The national
Danish Patient Registry has information on all patient
contacts with all clinical somatic and psychiatric hospital
departments in Denmark since 1977, including emergency
wards and outpatient clinics from 1995. The national
Danish Causes of Death Registry contains data on the
causes of all deaths in Denmark, as reported by hospitals
and general practitioners.28–30
Alzheimer’s disease was ICD8 code 290.10 and ICD10
codes F00 and G30. Vascular dementia was ICD10 F01 and
unspecified dementia was ICD8 290.18 and ICD10 F03. All
dementia included Alzheimer’s disease, vascular dementia,
and unspecified dementia. The quality of these registry
based dementia diagnoses has previously been validated,32
and was further validated by the well-known association
between the APOE e4 allele and Alzheimer’s disease and all
dementia in the present cohorts.30
Ischemic heart disease (ICD8 code 410-414 and ICD10
code I20-I25) was defined as myocardial infarction or
characteristic symptoms of stable angina pectoris.33 The
Table 1. Characteristics of study participants in the Copenhagen
General Population Study and the Copenhagen City Heart Study com-
bined as a function of ABCA7 rs4147929 genotype.
Characteristics GG genotype GA genotype AA genotype
No. of individuals,
%
74,039 (71.0) 27,656 (26.5) 2,563 (2.5)
Age, years 58 (48–67) 58 (48–67) 58 (47–67)
Female, % 55 56 56
Total cholesterol,
mmol/L
5.6 (4.9–6.3) 5.6 (4.9–6.3) 5.5 (4.8–6.3)
LDL cholesterol,
mmol/L
3.2 (2.6–3.9) 3.2 (2.6–3.9) 3.2 (2.6–3.8)
HDL cholesterol,
mmol/L
1.6 (1.2–1.9) 1.6 (1.3–1.9) 1.6 (1.3–1.9)
Triglycerides,
mmol/L
1.4 (1.0–2.0) 1.4 (1.0–2.1) 1.4 (0.9–2.0)
Body mass
index, kg/m2
26 (23–28) 26 (23–28) 25 (23–28)
Hypertension, % 59 59 58
Diabetes mellitus,
%
4 4 3
Smoking, % 20 21 20
High alcohol
consumption, %
17 17 17
Physical inactivity,
%
50 50 49
Post-menopausal,
%1
67 67 67
Hormonal
replacement,
%1
16 17 17
Lipid-lowering
therapy, %
11 11 11
Education
<8 years, %
12 12 12
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Values are median (interquartile range) or percentage (%), and are
from the day of enrollment (2003 and onward for the Copenhagen
General Population Study, and from 1991 to 1994 or 2001 to 2003 for
the Copenhagen City Heart Study). Hypertension was defined as use of
antihypertensive medication, systolic blood pressure ≥140 mmHg, and/
or diastolic blood pressure ≥90 mmHg. Diabetes mellitus was defined
as self-reported disease, use of insulin or oral hypoglycemic agents,
and/or non-fasting plasma glucose level >11 mmol/L (>198 mg/dL).
Smoking was defined as current smoking. Alcohol consumption was
defined as >14/21 units per week for women/men (1unit = 12 g alco-
hol, equivalent to 1 glass of wine or 1 beer [33 cl]). Physical inactivity
was defined as ≤4 h per week of light physical activity in leisure time.
Women reported menopausal status and use of hormonal replacement
therapy. Lipid-lowering therapy was primarily statins (yes/no), and low
education was <8 years of education.
1In women only.
Figure 1. Cumulative incidences of Alzheimer’s disease (A) and all
dementia (B) as a function of age and ABCA7 rs4147929 genotype.
Fine-Gray models, allowing for death and emigration as competing
events, were used. P-values were calculated using the “stcrreg”
command in Stata.
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quality of the myocardial infarction diagnosis has previ-
ously been validated.34
For cerebrovascular disease, validation of ICD codes
has been described previously.35 In brief, information on
diagnosis of cerebrovascular disease (ICD8 code 431–438
and ICD10 code I60-I69, G45), including ischemic cere-
brovascular disease (transitory ischemic attacks, amaurosis
fugax, and ischemic stroke) and hemorrhagic stroke was
validated by trained physicians using the WHO definition
of cerebrovascular disease.35
Follow-up time began at the establishment of the national
Danish Patient Registry (January 1st, 1977) or on the birth-
day of the participant, whichever came later. Follow-up
ended at occurrence of event, death (n = 9906), emigration
(n = 486) or on November 10th 2014 (last update of reg-
istry), whichever came first. Mean follow-up was 37.0 years
(range = 0–38 years) for dementia, 36.2 years (range = 0–
38 years) for ischemic heart disease and 36.6 years
(range = 0–38 years) for cerebrovascular disease. Because
of the complete Danish registries, no individuals were lost to
follow-up.
Genotyping
An ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems Inc, Foster City, CA, USA) and Taq-
Man-based assays were used to genotype ABCA7
(rs4147929) and APOE (rs7412 and rs429358). Variation at
rs7412 and rs429358 defines six common APOE genotypes
(ɛ22, ɛ32, ɛ42, ɛ33, ɛ43, and ɛ44), as previously described.30
APOE genotype was available for 100,426 individuals.
Laboratory analyses
Plasma total cholesterol, high-density lipoprotein (HDL)
cholesterol, triglycerides, apolipoprotein B and AI were
measured using standard hospital assays (Boehringer Man-
nheim GmbH, Mannheim, Germany; Konelab, Thermo Fis-
cher Scientific, Waltheim, MA, USA). Low-density
lipoprotein (LDL) cholesterol was calculated using the
Friedewald equation36 when plasma triglycerides were
≤4 mmol/L (≤352 mg/dL), and otherwise measured directly
(Konelab). ApoE was measured as previously described.30,37
Figure 2. Risk of Alzheimer’s disease, vascular dementia, unspecified dementia and all dementia as a function of ABCA7 rs4147929 genotype.
Analyses for Alzheimer’s disease, vascular, unspecified, and all dementia included 104,258 individuals. Hazard ratios were multifactorially adjusted
for age, sex, body mass index, hypertension, diabetes mellitus, smoking, alcohol consumption, physical inactivity, menopausal status and
hormonal replacement therapy (only women), lipid-lowering therapy, and education (left panel). Hazard ratios were further adjusted for APOE
genotype (100,427 participants) (middle panel). Analysis of individuals with APOE e33 genotype included 55,925 participants (right panel).
N=number; CI=confidence interval.
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Other covariates
Body mass index was measured weight in kilograms
divided by measured height in meters squared. Hyperten-
sion was a systolic blood pressure ≥140 mm Hg, a diastolic
blood pressure ≥90 mm Hg, and/or use of antihyperten-
sive medication. Diabetes mellitus was self-reported dis-
ease, use of insulin or oral hypoglycemic agents, and/or
non-fasting plasma glucose levels of more than 11 mmol/L
(>198 mg/dL). Smoking, alcohol consumption, physical
activity, postmenopausal status and hormonal replacement
therapy in women, use of lipid-lowering therapy, as well as
education, were all self-reported and dichotomized. Smok-
ing was current smoking. High alcohol consumption was
>14/21 units of alcohol per week for women/men (1 unit
alcohol~12 g). Physical inactivity was ≤4 h weekly of light
physical exercise in leisure time. Lipid-lowering therapy
was mainly statins (yes/no). Low educational level was
<8 years in school.
Statistical analysis
Stata/SE (Stata-Corp, College Station, TX, USA) version
14.0 was used. Missing data on continuous covariates
(0.21–1.16%) were imputed from age, sex, and the most
related continuous parameters; however, results reported
where similar without imputed data.
Cumulative incidences of Alzheimer’s disease and all
dementia were plotted against age and rs4147929 geno-
type, using the method of Fine-Gray,38 to account for
death and emigration as competing events. Cox propor-
tional hazards regression models with age as time scale,
left truncation (delayed entry), and censoring at death
were used to estimate hazard ratios for Alzheimer’s dis-
ease and all dementia as a function of rs4147929 geno-
type. Cox regression models were multifactorially adjusted
for age (as time scale), sex, body mass index, hyperten-
sion, smoking, alcohol intake, physical inactivity, post-
menopausal status, and hormonal replacement therapy in
women, lipid-lowering therapy and educational level. Fur-
thermore adjustments were for APOE genotype or total
cholesterol, LDL cholesterol, HDL cholesterol and triglyc-
erides. In sensitivity analyses we analyzed APOE e33 geno-
type individuals separately.
Meta-analyses were conducted using the user-written
metan command from Stata/S.E. v14.0 to estimate fixed
and random effects odds ratios from regression coeffi-
cients and standard errors for the genetic variant.
Results
Baseline characteristics of the 104,627 study participants
stratified by genotype are shown in Table 1. Risk factors were
equally distributed among genotypes (Table 1). Rs4147929
Figure 3. Meta-analysis of ABCA7 rs4147929 and risk of Alzheimer’s disease. Risk of Alzheimer’s disease per risk increasing allele. Horizontal
lines correspond to 95% confidence intervals by forest plots. Diamonds and broken vertical lines represent summary estimates. Confidence
interval for the summary estimate corresponds to the width of the diamond. Squares correspond to the weight of the study in the meta-analysis
from the fixed effects model (left column). CI=confidence interval.
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genotype frequencies were 71.0%, 26.5%, and 2.5% for GG,
GA, and AA, respectively, and did not deviate from the
Hardy–Weinberg expectation (P = 0.93). All results are for
the CGPS and CCHS combined unless otherwise stated.
ABCA7 rs4147929 and risk of Alzheimer’s
disease, vascular dementia, unspecified
dementia, and all dementia
Cumulative incidences of Alzheimer’s disease and all
dementia as a function of age and ABCA7 rs4147929
genotype increased stepwise from GG to GA to AA
(P = 0.02 and P = 0.07, respectively) (Fig. 1). Multifacto-
rially adjusted hazard ratios for Alzheimer’s disease were
1.07 (confidence interval 95% 0.93–1.23) for GA versus
GG and 1.72 (1.24–2.40) for AA versus GG (Fig. 2).
Results were similar after further adjustment for APOE
genotype (middle panel), or when analyses were per-
formed exclusively in APOE e33 carriers (right panel). No
associations between rs4147929 and vascular dementia, or
unspecified dementia were observed.
Meta-analysis of ABCA7 rs4147929 and risk
of Alzheimer’s disease
Meta-analysis included the two present cohorts of the
general Danish population and stage 1 and 2 from IGAP,
the latter including meta-analyzed data from 15 individ-
ual studies.5 For ABCA7 rs4147929 including 178,624
individuals, fixed- and random-effects meta-analyzed odds
ratios for Alzheimer’s disease per one allele increase were
1.15 (1.12–1.18) and 1.15 (1.12–1.18) (I2 = 0.0%; P for
heterogeneity = 0.95) (Fig. 3).
ABCA7 rs4147929 and risk of myocardial
infarction, ischemic heart disease, ischemic
stroke, ischemic cerebrovascular disease,
hemorrhagic stroke, and cerebrovascular
disease overall
Hazard ratios for ischemic heart disease were 1.01
(0.97–1.05) for rs4147929 GA versus GG genotype and
1.09 (0.97–1.23) for AA versus GG (Fig. 4). This
Figure 4. Risk of myocardial infarction, ischemic heart disease, ischemic stroke, ischemic cerebrovascular disease, hemorrhagic stroke, and all
cerebrovascular disease as a function of ABCA7 rs4147929 genotype. Hazard ratios were multifactorially adjusted for age, sex, body mass index,
hypertension, diabetes mellitus, smoking, alcohol consumption, physical inactivity, menopausal status and hormonal replacement therapy (only
women), lipid-lowering therapy, and education (left panel). Hazard ratios were further adjusted for lipid levels: total cholesterol, LDL and HDL
cholesterol, and triglycerides (middle panel). Number of participants varied slightly (from 100,377 to 104,208) according to availability of data.
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association was similar after further adjustment for total
cholesterol, LDL cholesterol, HDL cholesterol and
triglycerides (middle panel), or after adjustment for
APOE genotype (right panel). A slightly stronger associ-
ation was observed for myocardial infarction. ABCA7
rs4147929 genotype was not associated with ischemic
cerebrovascular disease or other cerebrovascular disease
subtypes.
Meta-analysis of ABCA7 rs4147929 and risk
of ischemic heart disease
Meta-analysis included the two present cohorts of the
general Danish population and CARDIoGRAMplusC4D
consortia data, the latter including data from 48 individ-
ual studies.39 For ABCA7 rs4147929 including 288,563
individuals, fixed and random-effects meta-analyzed odds
ratios for ischemic heart disease per one allele increase
were 1.01 (0.99–1.03) and 1.01 (0.99–1.03) (I2 = 0.0%; P
for heterogeneity = 0.42) (Fig. 5).
Lipid, lipoprotein, and apolipoprotein levels
as a function of ABCA7 rs4147929 genotype
The rs4147929 genotype was associated with a stepwise
marginally lower level of apolipoprotein B from GG to
GA to AA (P = 0.04) (Fig. 6). No other associations
between rs4147929 genotype and lipid, lipoprotein and
apolipoprotein levels were observed.
Discussion
The principle findings of this study are that a common
genetic variant in ABCA7 (rs4147929) is associated with
increased risk of Alzheimer’s disease, but not with
atherosclerosis-related diseases such as vascular dementia,
ischemic heart disease, or ischemic cerebrovascular dis-
ease. Importantly, the association with Alzheimer’s disease
remained after adjustment for APOE genotype and when
analyses were performed in APOE ɛ33 carriers alone.
These novel findings were observed in 104,258 individuals
from the general population.
To our knowledge, this is the first study to simultane-
ously assess risk of both dementia and atherosclerosis-
related diseases as a function of a common variant in
ABCA7, and the first study to conclude that these associa-
tions are independent of APOE genotype. Common varia-
tion in ABCA7 was first reported to be associated with
risk of Alzheimer’s disease in a large genome-wide associ-
ation study.6 Subsequently rare loss-of-function mutations
in ABCA7 were shown to be associated with Alzheimer’s
disease in Icelandic and Belgian populations.15,16 Since
Iceland has a modest, relatively isolated population,
genetic variants are more likely to be passed down
through generations than in larger mixed populations.40
Furthermore, analyses of rare mutations can be sensitive
to bias because of population stratification and hidden
relatedness.16 Therefore, such findings may not be appli-
cable to other populations. This study suggests ABCA7 as
Figure 5. Meta-analysis of ABCA7 rs4147929 and risk of ischemic heart disease. Risk of ischemic heart disease per risk increasing allele.
Horizontal lines correspond to 95% confidence intervals by forest plots. Diamonds and broken vertical lines represent summary estimates.
Confidence interval for the summary estimate corresponds to the width of the diamond. Squares correspond to the weight of the study in the
meta-analysis from the fixed effects model (left column). CI=confidence interval.
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a risk gene for Alzheimer’s disease also in the general
population.
The exact mechanism underlying our findings is
unclear; however, experimental and human evidence sug-
gests plausible explanations for the present data. The
studies on loss-of-function mutations in ABCA7 suggest
that loss of ABCA7 could be a potential pathogenic mech-
anism underlying Alzheimer’s disease,15,16 but also func-
tional studies of a common missense variant in exon 33
(rs3752246, p.Gly1527Ala) support this.41 Rs3752246 was
identified in a North American study,42 and is in high LD
with the present rs4147929 variant (http://snipa.he
lmholtz-muenchen.de/snipa3/, r2=0.97). The rs3752246
variant is located in a predicted post-translational myris-
toylation site.41 Expression of human ABCA7 (hABCA7)
carrying the rs3752246 risk allele led to increases in
secreted amyloid-b40 and amyloid-b42 and b-secretase
activity in CHO- and HEK-AbPPSwe cells, and molecular
weight determination showed loss of post-translational
modification in the risk-allele peptide spanning position
1527.41 Another common variant, rs3764650, was the first
top significant hit reported in ABCA7.6 This variant is
located in intron 13, and is not in strong LD with the
present rs4147929 (http://snipa.helmholtz-muenchen.de/
snipa3/, r2 = 0.21), and therefore most likely does not
contribute to the present findings.
Biologically, ABCA7 is important for microglial phago-
cytosis of amyloid-b in the brain.11 Kim et al. found that
ABCA7 knockout mice crossed with J20 amyloidogenic
mice had double the amount of insoluble amyloid-b con-
centration and plaque levels in the brain compared to J20
mice.24 The ability to phagocytose amyloid-b-oligomers
in isolated microglia and macrophages was reduced in
ABCA7 knockout mice compared to wild-type mice.12
This study additionally showed that apoE concentrations
in mice were not altered by ABCA7 loss, suggesting an
apoE independent pathway for ABCA7. Finally, Sakae
et al. reported that ABCA7 deficiency altered brain lipid
profile and impaired memory in ABCA7 knock-out
mice.43 Since we do not find any association between
ABCA7 and other types of dementia with vascular com-
ponents, it is likely that the function of ABCA7 predomi-
nantly is through microglial amyloid-b clearance within
the brain.
Figure 6. Lipid, lipoprotein, and apolipoprotein levels as a function of
ABCA7 rs4147929 genotype. Values are geometric meanSEM for
apolipoprotein E and triglyceride levels and otherwise meanSEM.
P-values by Cuzick’s test for trend. To convert cholesterol to mg/dL,
divide by 0.0259; to convert triglycerides to mg/dL, divide by 0.0113.
Abbreviations: SEM=standard error of the mean; HDL=high-density
lipoprotein; LDL=low-density lipoprotein; Apo=apolipoprotein.
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ABCA7 function was initially reported to be related to
cholesterol and phospholipid efflux, however, with con-
flicting results.10 Previous mice studies showed that
ABCA7 was involved in apolipoprotein-mediated phos-
pholipid release, whereas results from studies on choles-
terol release were less convincing.10 In our study, the risk
of myocardial infarction was marginally increased for
rs4147929 AA versus GG genotype, and for ischemic heart
disease a similar trend was observed. For this reason, we
tested the association between ischemic heart disease and
ABCA7 rs4147929 genotype per risk increasing allele, in a
meta-analysis including data from the CARDIoGRAM-
plusC4D consortium. The meta-analysis did not show any
association between ABCA7 rs4147929 and risk of
ischemic heart disease, in agreement with the lack of asso-
ciation between rs4147929 genotype and lipid and
lipoprotein levels. This suggest that our findings for
myocardial infarction represent a spurious observation;
however, we naturally cannot totally exclude the possibil-
ity that our finding on myocardial infarction is true and
may be due to other mechanisms than coronary artery
atherosclerosis, such as small vessel disease of various
pathological origin.
Strengths of this study are the large, well-characterized,
ethnically homogenous cohort of the general population
with no individuals lost to follow-up. Additional strengths
are that risk of Alzheimer’s disease per risk increasing allele
in both CGPS and CCHS for ABCA7 rs4147929 were com-
parable to the estimates from IGAP stages 1 and 2, and that
between study heterogeneity of the meta-analysis estimate
was 0.0%. Since the ABCA7 locus is on chromosome 19, it
may be suspected that at least part of the ABCA7 associa-
tion could be due to linkage disequilibrium with APOE.
However, we now robustly show that the association
between genetic variation in ABCA7 and risk of Alzheimer’s
disease is independent of the strong APOE ɛ4 allele. Fur-
thermore, the quality of the Danish register- based demen-
tia diagnosis has previously been validated.32 The core
clinical criteria for Alzheimer’s disease have been shown to
provide very good diagnostic accuracy and utility in most
patients,44 and the quality of Alzheimer’s diagnoses was
further validated by the presence of the well-known associ-
ation with the APOE ɛ4 allele in our two study cohorts.30
Additionally, characteristics of participants in the three
genotype groups were similar, largely making confounding
of the genetic variant unlikely, and thus supporting causal-
ity of the ABCA7 pathway. A potential limitation of our
study may be that we only studied white individuals from
an ethnically homogeneous population. For instance, a
GWAS risk allele (rs115550680) in African Americans was
prevalent in this ethnic group in contrast to non-hispanic
whites,45 and was in high LD with a 44-base pair exonic
deletion (rs142076058). This common ABCA7 deletion
could represent an ethnic-specific pathogenic alteration in
Alzheimer’s disease. The rs4147929 variant is, however,
common in most ethnic groups (www.ensembl.org) and
the present findings are therefore likely to be applicable to
these ethnicities.
In summary, a common genetic variant in ABCA7
was associated with high risk of Alzheimer’s disease
independent of APOE genotype in the general popula-
tion. The lack of association between the ABCA7
variant and vascular dementia, ischemic heart disease,
ischemic cerebrovascular disease and lipid and lipopro-
tein levels suggests that ABCA7 is not likely to play a
role in atherosclerosis. Our findings thus support the
suggested role of ABCA7 in Alzheimer’s disease
pathology by phagocytic clearance of amyloid-b in the
brain.
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